Mainz Biomed, Liquid Biosciences make discovery of mRNA biomarkers

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA biomarkers for the non-invasive detection of pancreatic cancer with a blood test. The parties, under the Agreement, plan to develop this blood-based test for potential future FDA applications. Under the terms of the Agreement, the Company has the rights to develop a test using Liquid’s biomarkers through an exclusive license with the unilateral option to acquire the exclusive global rights to the gene expression biomarkers which have demonstrated a high degree of effectiveness in detecting pancreatic cancer. The financial terms of the Agreement include both a license fee and a royalty on future revenues in the event of the exercise of the option.